Cspc Baike (shandong) Biopharmaceutical Co., Ltd.

This study tested a new weekly injection (HD1916) similar to semaglutide for weight loss in 462 obese adults without diabetes. Participants received the drug for 44 weeks, and researchers measured how much weight they lost and any side effects. The goal was to see if this treatme…

This Phase 3 trial tested a new weekly injection called TG103, combined with the common diabetes pill metformin, in 632 adults with type 2 diabetes. The goal was to see if TG103 could lower blood sugar better than an existing weekly shot (dulaglutide) over 28 weeks. Participants …

This study tested a new weekly injection called TG103 in 465 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. Participants received either a low dose, a higher dose, or a placebo for several weeks. The main goal was to see if TG103…